Claim OwnershipBioTech Nation ... with Dr. Moira Gunn
Subscribed: 421Played: 3,790
Subscribe
© Tech Nation Media
Description
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues.
134 Episodes
Reverse
Tech Nation Health Chief Correspondent
Daniel Kraft reports in on the BioTech Nation session from NextMed Health 2025
This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.
This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills.
This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year.
This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health.
This week on BioTech Nation, Dr. Eric Topol, professor and Executive Vice President at Scripps Research and author of "Super Agers … An Evidenced-Based Approach to Longevity", breaks down what science really says about aging well and what is just marketing. From immune-boosting cell therapy to the myth of magic longevity pills, Dr. Topol explains how evidence-based prevention, personalized health data, and AI are changing the future of aging.
This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases.
Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.
This week on BioTech Nation, Robert Blum, CEO of CytoKinetics, joins me to talk about the company’s decades-long mission to keep hearts beating stronger and longer. With one heart drug under FDA review and more in the pipeline, CytoKinetics is working to address the full spectrum of heart failure, from weak hearts to overactive ones, and even exploring muscle health beyond the heart to support healthy aging.
This week on BioTech Nation, BioSTEM Technologies CEO Jason Matuszewski explains how donated placental tissue is being used to treat chronic wounds that just won’t heal, from diabetic ulcers to pressure sores. With millions affected and traditional care often falling short, BioSTEM’s approach offers a new way to support healing and reduce scarring.
This week on BioTech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years.
This week on BioTech Nation, Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, returns with highlights from the 2025 NextMed Health conference. From AI-powered health agents to voice-based disease detection, hear what’s emerging at the intersection of medicine, technology, and global health equity.
Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.
This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.
This week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, discusses their groundbreaking success in treating drug-resistant epilepsy. With a single, targeted delivery of lab-grown brain cells, Neurona is offering not just symptom control but the possibility of long-term seizure relief. This is Part 1 of a two-part series exploring the future of regenerative medicine in neurology.
This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.
This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.
This week on BioTech Nation, Luminary Therapeutics CEO Jeff Liter shares how his team is working to make advanced cell therapy easier to access and more affordable. Instead of using each patient’s own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose.
This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.
This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.
Comments
Download from Google Play
Download from App Store
United States